Adult patients with
bacterial infections of the lower respiratory tract were given either
cefoperazone or
cefamandole in a multicenter clinical study of the clinical and bacteriologic efficacy of
cefoperazone. Clinical diagnoses included
pneumonia,
bronchitis,
lung abscess, and
bronchiectasis. Efficacy was evaluated in 119 patients given
cefoperazone and 73 patients given
cefamandole. Major pathogens isolated included Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Satisfactory clinical responses were noted for 96% of the patients in both treatment groups, including 14 of 17 patients given
cefoperazone who were primarily infected with P. aeruginosa. Satisfactory bacteriologic responses were noted for 88% of the group given
cefoperazone and 89% of the group given
cefamandole. Adverse reactions related to the
antibiotic occurred infrequently in each treatment group. The results of this study indicate that
cefoperazone is a safe and effective
antibiotic for the treatment of lower
respiratory tract infections due to S. pneumoniae, H. influenzae, S. aureus, and many gram-negative bacilli, including susceptible strains of P. aeruginosa, in adult patients.